Biohaven Ltd. Form 8-K Summary
Business Context and Reporting Period
Date: April 28, 2025
Company: Biohaven Ltd.
Event: Entry into a Material Definitive Agreement (Note Purchase Agreement) with purchasers led by Beetlejuice SA LLC as purchaser agent. The agreement involves senior secured notes tied to the commercial performance and regulatory approval of the company's drug candidate, troriluzole.
Key Financial Metrics and Deal Structure
This filing details a potential capital raise of up to $600 million structured in three tranches:
- First Notes: $250 million initial tranche (subject to customary closing conditions).
- Second Notes: Up to $150 million in up to three purchases by June 30, 2026, contingent on FDA approval of troriluzole.
- Third Notes: Up to $200 million in up to four purchases at the Issuer's option, proceeds restricted to permitted acquisitions.
Repayment Terms:
- Revenue Payments: Initially 6.25% of global net sales of troriluzole, payable quarterly. This rate increases pro rata with Second Notes purchases.
- Milestone Payment: 35% of the Funded Amount upon FDA or EMA approval of troriluzole or other products.
- True-Up Payment: If the "Test Date Condition" (total payments equaling funded amount by Dec 31, 2030) is not met, a one-time payment is required to cover the shortfall.
- Cap Amount: Total payments are capped at multiples of the funded amount (ranging from 1.4x to 2.25x depending on performance and timing).
Collateral: Obligors granted a security interest in cash, equity interests, and specific assets related to troriluzole.
Material Changes and Covenants
The agreement imposes significant affirmative and negative covenants restricting the company's ability to:
- Incur additional indebtedness or grant liens.
- Merge, consolidate, or dispose of assets.
- Make investments, acquisitions, or affiliate transactions.
- Pay dividends, make distributions, or repurchase stock.
Termination Options:
- Call Option: Issuer may repurchase notes in full at any time upon notice.
- Put Option: Purchasers may force repurchase upon defaults, bankruptcy, change of control, or key man events. Repurchase prices range from 120% to 225% of the funded amount depending on timing and performance metrics.
Guidance, Outlook, and Risks
Use of Proceeds: Working capital, permitted business purposes, and funding permitted acquisitions (Third Notes only).
Key Risks and Contingencies:
- Regulatory Approval: The Second Notes tranche is explicitly contingent on FDA approval of troriluzole.
- Commercial Performance: Repayment obligations are directly tied to the net sales of troriluzole. Failure to meet sales targets by the Test Date (Dec 31, 2030) triggers higher revenue payment rates or a True-Up Payment.
- Liquidity Constraints: Strict covenants limit financial flexibility regarding dividends, stock buybacks, and new debt.
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the investment but does not contain additional narrative commentary within the 8-K text itself.
Investor Verification Checklist
- Verify the exact closing date and conditions for the $250 million First Notes tranche.
- Confirm the current regulatory status of troriluzole regarding FDA approval for obsessive compulsive disorder or spinocerebellar ataxia.
- Review the full Note Purchase Agreement (Exhibit 10.1) for specific definitions of "Net Sales" and "Permitted Acquisitions."
- Assess the impact of the 6.25% (or higher) revenue royalty on future profit margins for troriluzole.
- Monitor the company's ability to meet the "Test Date Condition" by December 31, 2030, to avoid the True-Up Payment and increased royalty rates.